AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Pliant Therapeutics Reports Promising Interim Data for PLN-101095.
ByAinvest
Thursday, Dec 4, 2025 7:36 am ET1min read
Pliant Therapeutics reported interim data from its Phase 1 trial evaluating PLN-101095, a dual selective inhibitor of αvβ8 and αvβ1, in combination with pembrolizumab for ICI-refractory advanced or metastatic solid tumors. The data showed one complete response and three partial responses in heavily pretreated patients. The company plans to initiate a Phase 1b expansion trial in 2026, supported by its strong cash position, which is expected to last through 2028.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet